ReviewPaediatric drugs2013
Pediatric allergic rhinitis and asthma: can the march be halted?
Review in Paediatric drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Association between combined allergic rhinitis and asthma syndrome in children and nitric oxide: mechanisms, clinical significance, and research progress.Frontiers in immunology · 2026Review
- Allergen Immunotherapy for the Prevention and Treatment of Asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Multi-biofluid metabolomics analysis of allergic respiratory rhinitis and asthma in early childhood.The World Allergy Organization journal · 2025Article
- The MaDo real-life study of dose adjustment of allergen immunotherapy liquid formulations in an indication of respiratory allergic disease: Reasons, practices, and outcomes.Frontiers in allergy · 2022Article
- Allergies, Allergic Comorbidities and the Home Environment in Pediatric Asthma in Southern Florida.International journal of environmental research and public health · 2021Article
- Childhood Allergy Disease, Early Diagnosis, and the Potential of Salivary Protein Biomarkers.Mediators of inflammation · 2021Review
- Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma.Allergy · 2019Article
- Mechanisms by Which Atopic Dermatitis Predisposes to Food Allergy and the Atopic March.Allergy, asthma & immunology research · 2019Review
- Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?Paediatric drugs · 2017Article
- Efficacy of a leukotriene receptor antagonist for pediatric cedar pollen allergy complicated by asthma.Experimental and therapeutic medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.
Indexed as
Identifiers
23955538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.